<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035953</url>
  </required_header>
  <id_info>
    <org_study_id>SMA-AIS-003</org_study_id>
    <nct_id>NCT05035953</nct_id>
  </id_info>
  <brief_title>Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke</brief_title>
  <official_title>Effect of Thrombolysis Combined With Edaravone Dexborneol for Acute Ischemic Stroke Patients: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Stroke Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the safety and efficacy of edaravone dexborneol for the treatment of acute&#xD;
      ischemic stroke patients who received thrombolysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 13, 2021</start_date>
  <completion_date type="Anticipated">March 13, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 13, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of symptomatic intracranial hemorrhage</measure>
    <time_frame>36-48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of symptomatic intracranial hemorrhage</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of intracranial hemorrhage</measure>
    <time_frame>36-48 hours, 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of Participants With modified Rankin Scale (mRS) Score 0 to 1</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the NIH stroke scale (NIHSS) from the baseline</measure>
    <time_frame>36-48 hours, 7, 14 and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of Participants With Barthel Index (BI) score greater than or equal to 95</measure>
    <time_frame>14 and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular recanalization</measure>
    <time_frame>36-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Brain Barrier Permeability</measure>
    <time_frame>36-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Encephaledema</measure>
    <time_frame>36-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Death</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>Edaravone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Edaravone Dexborneol injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Edaravone Dexborneol matching injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edaravone Dexborneol</intervention_name>
    <description>Edaravone Dexborneol 37.5 mg (containing Edaravone 30 mg and Dexborneol 7.5 mg), BID, 14 days, addition to thrombolysis</description>
    <arm_group_label>Edaravone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Edaravone Dexborneol matching injection, addition to thrombolysis</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute ischemic stroke;&#xD;
&#xD;
          -  18 to 80 years of age;&#xD;
&#xD;
          -  There are clear signs of neurological deficit: 8≤NIHSS score≤24;&#xD;
&#xD;
          -  Received alteplase thrombolysis therapy within 4.5 hours after onset;&#xD;
&#xD;
          -  Patients signed written inform consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients need endovascular therapy or bridge therapy;&#xD;
&#xD;
          -  Cranial CT scan finds intracranial bleeding disorders: hemorrhagic stroke, epidural&#xD;
             hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage;&#xD;
&#xD;
          -  Severe head trauma or stroke, intracranial tumor or large intracranial aneurysm within&#xD;
             3 months;&#xD;
&#xD;
          -  Intracranial or intraspinal surgery within 3 months;&#xD;
&#xD;
          -  Active visceral hemorrhage&#xD;
&#xD;
          -  Major surgery within 2 weeks or arterial puncture within 1 week that is difficult to&#xD;
             compress the hemostatic site;&#xD;
&#xD;
          -  Unknown onset time;&#xD;
&#xD;
          -  Rapid improvement of symptoms or mild symptoms before thrombolysis therapy;&#xD;
&#xD;
          -  A platelet count below 100,000/mm3 indicates a propensity for acute bleeding;&#xD;
&#xD;
          -  Therapeutic neuroprotective agents have been applied after onset of stroke, including&#xD;
             commercially available edaravone, nimodipine, ganglioside, citicoline, piracetam,&#xD;
             butyl benzene peptides, Urinary Kallidinogenase;&#xD;
&#xD;
          -  Patients with severe mental disorders and dementia;&#xD;
&#xD;
          -  ALT or AST is greater than 2.0×ULN or previously known liver diseases, such as acute&#xD;
             hepatitis, chronic active hepatitis, liver cirrhosis;&#xD;
&#xD;
          -  Serum Creatinine (SCr) is greater than 1.5×ULN, Creatinine Clearance (CrCl) is less&#xD;
             than 50 ml/min or previously known severe renal diseases;&#xD;
&#xD;
          -  Patients with malignant tumors or severe systemic disease;&#xD;
&#xD;
          -  allergic to edaravone , (+)-Borneol or related excipients;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Have major surgery within 4 weeks before enrollment;&#xD;
&#xD;
          -  Participated in other clinical studies within 30 days before randomization; or&#xD;
             participating in other clinical trials at present;&#xD;
&#xD;
          -  The investigators consider the patients are not suitable for this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qiang Dong</last_name>
    <phone>86-21-52887142</phone>
    <email>qiang_dong163@163.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Qiang Dong</investigator_full_name>
    <investigator_title>MD, PhD, Director of Neurology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edaravone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

